What is Adtalem Global's gross profit margin?

What were the key takeaways from Adtalem Global’s earnings call?

What is the market's earnings forecast for Adtalem Global next quarter?

What guidance did Adtalem Global's management provide for the next earnings period?

Did Adtalem Global beat or miss consensus estimates last quarter?

What does Adtalem Global do and what are its main business segments?

What factors drove the changes in Adtalem Global's revenue and profit?

What is Adtalem Global's latest dividend and current dividend yield?

- **Revenue Growth**: 10.8% YoY to $462.3M, driven by 13.6% enrollment rise at Walden and 2.2% at Chamberlain.
- **Chamberlain Challenges**: Q1 post-licensure nursing growth stalled due to marketing execution issues, but pre-licensure BSN added 750 students.
- **AI Expansion**: Google Cloud partnership to launch AI credentials for health care professionals, with no additional student costs.
- **Financial Health**: $319M trailing free cash flow, $1.75 EPS (35.7% YoY growth), and $8M share buybacks.
- **Guidance**: Full-year revenue $1.9B-$1.94B, EPS $7.60-$7.90, despite Q2/Q3 softness at Chamberlain.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue reached $462.3 million, up 10.8% year-over-year, driven by 13.6% enrollment growth at Walden and 2.2% at Chamberlain. Adjusted EBITDA expanded by 15.8% to $112 million.
- **Chamberlain Challenges**: Post-licensure nursing enrollment growth slowed due to marketing execution failures and conversion inefficiencies, though pre-licensure BSN online programs added 750 students sequentially.
- **Strategic Initiatives**: Expanded AI partnerships with Google Cloud for health care credentials, launched MedPath program for frontline workers, and repurchased $8 million in shares.
- **Financial Strength**: Generated $319 million in trailing 12-month free cash flow, with $265 million in cash and $500 million revolving credit facility.

**【CFO Financial Commentary】**
- **Revenue by Segment**: Chamberlain ($179.2M, +6.7%), Walden ($190M, +17.6%), Medical/Veterinary ($93.1M, +5.9%).
- **Margins**: Consolidated adjusted EBITDA margin 24.2% (up 100bps), Chamberlain margin 19.6% (down 240bps due to reinvestment).
- **Cash Flow**: $64.9M adjusted net income, $1.75 EPS (up 35.7%). Repurchased 57,000 shares at $134 avg price.

**【Q&A Highlights】**
- **Chamberlain Execution**: Softness in Q2/Q3 due to marketing missteps, but 11th straight quarter of enrollment growth. Plans to streamline funnel, reallocate marketing spend, and implement leadership changes.
- **Competitive Position**: Maintains RN to BSN market leadership; no evidence of share loss despite enrollment deceleration.
- **AI Partnerships**: Google Cloud collaboration to launch AI credentials for students and clinicians, with no incremental costs.
- **Government Impact**: Minimal exposure to military tuition assistance; no material impact from DOE fraud verification efforts.
- **Investor Day**: February 2026 event to detail long-term strategy and capital allocation.

ATGE

ATGE fundamentals

You can ask Aime